Brief
The Signatera Test for Patients Previously Diagnosed with Cancer
Condition
Cancer
16 August 2022
Published on 16 Aug 2022
Last Updated on 16 Aug 2022
This Horizon Scanning Brief provides an assessment of the Signatera test to detect molecular residual disease in patients previously diagnosed with cancer.
The Signatera Test for Patients Previously Diagnosed with Cancer [PDF, 1.3 MB] (opens in new tab)